Your session is about to expire
What is Methyldopa And Hydrochlorothiazide
HydrochlorothiazideThe Generic name of this drug
Treatment SummaryHydrochlorothiazide is a commonly prescribed medication used to treat fluid retention and high blood pressure. It is less commonly used now than angiotensin converting enzyme inhibitors, which are often combined with hydrochlorothiazide in combination drugs. Hydrochlorothiazide is approved by the FDA and was first introduced in 1959.
Esidrixis the brand name
Methyldopa And Hydrochlorothiazide Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Esidrix
Hydrochlorothiazide
1959
2181
Approved as Treatment by the FDA
Hydrochlorothiazide, also called Esidrix, is approved by the FDA for 22 uses including Stroke and inadequate response to other therapeutic measures .Stroke
Used to treat Cerebrovascular Accident in combination with Losartan
inadequate response to other therapeutic measures
Used to treat inadequate response to other therapeutic measures in combination with Spironolactone
Antihypertensive Treatment
Used to treat Antihypertensive Treatment in combination with Eprosartan
Diuretics
Used to treat Hypokalemia caused by diuretics in combination with Amiloride
Left Ventricular Hypertrophy
Used to treat Left Ventricular Hypertrophy in combination with Losartan
Hypertensive disease
Used to treat High Blood Pressure (Hypertension) in combination with Losartan
Antepartum magnesium sulfate prophylaxis
Helps manage prophylaxis of preeclampsia
Sodium retention
Used to treat Sodium retention in combination with Spironolactone
Congestive Heart Failure
Used to treat Congestive Heart Failure (CHF) in combination with Spironolactone
Swollen feet or ankles
Used to treat Edema in combination with Triamterene
hypokalemia with solo treatment
Used to treat hypokalemia with solo treatment in combination with Triamterene
Ascites
Used to treat Ascites in combination with Spironolactone
restriction of fluid and sodium
Used to treat restriction of fluid and sodium in combination with Spironolactone
Edema
Helps manage Premenstrual tension with edema
inadequate control of blood pressure with monotherapy
Used to treat inadequate control of blood pressure with monotherapy in combination with Aliskiren
calcium channel blockers
Used to treat calcium channel blockers in combination with Eprosartan
Therapeutic procedure
Used to treat inadequate response to treatment in combination with Spironolactone
Bedrest
Used to treat Bedrest in combination with Spironolactone
Cirrhosis
Used to treat Cirrhosis of the Liver in combination with Spironolactone
blood pressure inadequately controlled with monotherapy
Used to treat blood pressure inadequately controlled with monotherapy in combination with Irbesartan
Nephrotic Syndrome
Used to treat Nephrotic Syndrome in combination with Spironolactone
Hypertensive disease
Used to treat Hypertension, Essential Hypertension in combination with Spironolactone
Effectiveness
How Methyldopa And Hydrochlorothiazide Affects PatientsHydrochlorothiazide helps the body get rid of extra water and salt by blocking the absorption of these substances in the kidneys. The amount of hydrochlorothiazide taken can vary from person to person, from 25-100mg. People with reduced kidney or liver function should be extra careful when taking this drug.
How Methyldopa And Hydrochlorothiazide works in the bodyHydrochlorothiazide works by blocking sodium from being reabsorbed in the distal convoluted tubule of the kidneys. Normally, this sodium is moved from the tubule to the cells on the outside of the tubule with help from an ATPase enzyme. Hydrochlorothiazide stops this process by blocking a transporter molecule called SLC12A3. This stops the concentration gradient from forming and reduces the amount of water that is reabsorbed back into the body.
When to interrupt dosage
The advisable dose of Methyldopa And Hydrochlorothiazide is determined by the identified condition, such as Antepartum magnesium sulfate prophylaxis, blood pressure inadequately managed with monotherapy and antihypertensives. The amount of dosage is contingent upon the mode of administration (e.g. Tablet, coated - Oral or Oral) highlighted in the following table.Condition
Dosage
Administration
Edema
12.5 mg, , 25.0 mg, 50.0 mg, 15.0 mg, 6.25 mg, 0.25 mg, 0.125 mg, 100.0 mg, 2.5 mg/mg, 5.0 mg/mg, 30.0 mg, 0.0125 mg
Oral, Tablet, film coated, Tablet, film coated - Oral, , Tablet, Tablet - Oral, Capsule - Oral, Capsule, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, coated, Tablet, coated - Oral
Nephrotic Syndrome
12.5 mg, , 25.0 mg, 50.0 mg, 15.0 mg, 6.25 mg, 0.25 mg, 0.125 mg, 100.0 mg, 2.5 mg/mg, 5.0 mg/mg, 30.0 mg, 0.0125 mg
Oral, Tablet, film coated, Tablet, film coated - Oral, , Tablet, Tablet - Oral, Capsule - Oral, Capsule, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, coated, Tablet, coated - Oral
Sodium retention
12.5 mg, , 25.0 mg, 50.0 mg, 15.0 mg, 6.25 mg, 0.25 mg, 0.125 mg, 100.0 mg, 2.5 mg/mg, 5.0 mg/mg, 30.0 mg, 0.0125 mg
Oral, Tablet, film coated, Tablet, film coated - Oral, , Tablet, Tablet - Oral, Capsule - Oral, Capsule, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, coated, Tablet, coated - Oral
Left Ventricular Hypertrophy
12.5 mg, , 25.0 mg, 50.0 mg, 15.0 mg, 6.25 mg, 0.25 mg, 0.125 mg, 100.0 mg, 2.5 mg/mg, 5.0 mg/mg, 30.0 mg, 0.0125 mg
Oral, Tablet, film coated, Tablet, film coated - Oral, , Tablet, Tablet - Oral, Capsule - Oral, Capsule, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, coated, Tablet, coated - Oral
Congestive Heart Failure
12.5 mg, , 25.0 mg, 50.0 mg, 15.0 mg, 6.25 mg, 0.25 mg, 0.125 mg, 100.0 mg, 2.5 mg/mg, 5.0 mg/mg, 30.0 mg, 0.0125 mg
Oral, Tablet, film coated, Tablet, film coated - Oral, , Tablet, Tablet - Oral, Capsule - Oral, Capsule, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, coated, Tablet, coated - Oral
Bedrest
12.5 mg, , 25.0 mg, 50.0 mg, 15.0 mg, 6.25 mg, 0.25 mg, 0.125 mg, 100.0 mg, 2.5 mg/mg, 5.0 mg/mg, 30.0 mg, 0.0125 mg
Oral, Tablet, film coated, Tablet, film coated - Oral, , Tablet, Tablet - Oral, Capsule - Oral, Capsule, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, coated, Tablet, coated - Oral
Renal tubular acidosis
12.5 mg, , 25.0 mg, 50.0 mg, 15.0 mg, 6.25 mg, 0.25 mg, 0.125 mg, 100.0 mg, 2.5 mg/mg, 5.0 mg/mg, 30.0 mg, 0.0125 mg
Oral, Tablet, film coated, Tablet, film coated - Oral, , Tablet, Tablet - Oral, Capsule - Oral, Capsule, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, coated, Tablet, coated - Oral
inadequate control of blood pressure with monotherapy
12.5 mg, , 25.0 mg, 50.0 mg, 15.0 mg, 6.25 mg, 0.25 mg, 0.125 mg, 100.0 mg, 2.5 mg/mg, 5.0 mg/mg, 30.0 mg, 0.0125 mg
Oral, Tablet, film coated, Tablet, film coated - Oral, , Tablet, Tablet - Oral, Capsule - Oral, Capsule, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, coated, Tablet, coated - Oral
inadequate response to other therapeutic measures
12.5 mg, , 25.0 mg, 50.0 mg, 15.0 mg, 6.25 mg, 0.25 mg, 0.125 mg, 100.0 mg, 2.5 mg/mg, 5.0 mg/mg, 30.0 mg, 0.0125 mg
Oral, Tablet, film coated, Tablet, film coated - Oral, , Tablet, Tablet - Oral, Capsule - Oral, Capsule, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, coated, Tablet, coated - Oral
Hypertensive disease
12.5 mg, , 25.0 mg, 50.0 mg, 15.0 mg, 6.25 mg, 0.25 mg, 0.125 mg, 100.0 mg, 2.5 mg/mg, 5.0 mg/mg, 30.0 mg, 0.0125 mg
Oral, Tablet, film coated, Tablet, film coated - Oral, , Tablet, Tablet - Oral, Capsule - Oral, Capsule, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, coated, Tablet, coated - Oral
prophylaxis of calcium nephrolithiasis
12.5 mg, , 25.0 mg, 50.0 mg, 15.0 mg, 6.25 mg, 0.25 mg, 0.125 mg, 100.0 mg, 2.5 mg/mg, 5.0 mg/mg, 30.0 mg, 0.0125 mg
Oral, Tablet, film coated, Tablet, film coated - Oral, , Tablet, Tablet - Oral, Capsule - Oral, Capsule, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, coated, Tablet, coated - Oral
Stroke
12.5 mg, , 25.0 mg, 50.0 mg, 15.0 mg, 6.25 mg, 0.25 mg, 0.125 mg, 100.0 mg, 2.5 mg/mg, 5.0 mg/mg, 30.0 mg, 0.0125 mg
Oral, Tablet, film coated, Tablet, film coated - Oral, , Tablet, Tablet - Oral, Capsule - Oral, Capsule, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, coated, Tablet, coated - Oral
Nephrolithiasis
12.5 mg, , 25.0 mg, 50.0 mg, 15.0 mg, 6.25 mg, 0.25 mg, 0.125 mg, 100.0 mg, 2.5 mg/mg, 5.0 mg/mg, 30.0 mg, 0.0125 mg
Oral, Tablet, film coated, Tablet, film coated - Oral, , Tablet, Tablet - Oral, Capsule - Oral, Capsule, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, coated, Tablet, coated - Oral
Diabetes Insipidus
12.5 mg, , 25.0 mg, 50.0 mg, 15.0 mg, 6.25 mg, 0.25 mg, 0.125 mg, 100.0 mg, 2.5 mg/mg, 5.0 mg/mg, 30.0 mg, 0.0125 mg
Oral, Tablet, film coated, Tablet, film coated - Oral, , Tablet, Tablet - Oral, Capsule - Oral, Capsule, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, coated, Tablet, coated - Oral
Cirrhosis
12.5 mg, , 25.0 mg, 50.0 mg, 15.0 mg, 6.25 mg, 0.25 mg, 0.125 mg, 100.0 mg, 2.5 mg/mg, 5.0 mg/mg, 30.0 mg, 0.0125 mg
Oral, Tablet, film coated, Tablet, film coated - Oral, , Tablet, Tablet - Oral, Capsule - Oral, Capsule, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, coated, Tablet, coated - Oral
restriction of fluid and sodium
12.5 mg, , 25.0 mg, 50.0 mg, 15.0 mg, 6.25 mg, 0.25 mg, 0.125 mg, 100.0 mg, 2.5 mg/mg, 5.0 mg/mg, 30.0 mg, 0.0125 mg
Oral, Tablet, film coated, Tablet, film coated - Oral, , Tablet, Tablet - Oral, Capsule - Oral, Capsule, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, coated, Tablet, coated - Oral
Antepartum magnesium sulfate prophylaxis
12.5 mg, , 25.0 mg, 50.0 mg, 15.0 mg, 6.25 mg, 0.25 mg, 0.125 mg, 100.0 mg, 2.5 mg/mg, 5.0 mg/mg, 30.0 mg, 0.0125 mg
Oral, Tablet, film coated, Tablet, film coated - Oral, , Tablet, Tablet - Oral, Capsule - Oral, Capsule, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, coated, Tablet, coated - Oral
Antihypertensive Treatment
12.5 mg, , 25.0 mg, 50.0 mg, 15.0 mg, 6.25 mg, 0.25 mg, 0.125 mg, 100.0 mg, 2.5 mg/mg, 5.0 mg/mg, 30.0 mg, 0.0125 mg
Oral, Tablet, film coated, Tablet, film coated - Oral, , Tablet, Tablet - Oral, Capsule - Oral, Capsule, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, coated, Tablet, coated - Oral
blood pressure inadequately controlled with monotherapy
12.5 mg, , 25.0 mg, 50.0 mg, 15.0 mg, 6.25 mg, 0.25 mg, 0.125 mg, 100.0 mg, 2.5 mg/mg, 5.0 mg/mg, 30.0 mg, 0.0125 mg
Oral, Tablet, film coated, Tablet, film coated - Oral, , Tablet, Tablet - Oral, Capsule - Oral, Capsule, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, coated, Tablet, coated - Oral
calcium channel blockers
12.5 mg, , 25.0 mg, 50.0 mg, 15.0 mg, 6.25 mg, 0.25 mg, 0.125 mg, 100.0 mg, 2.5 mg/mg, 5.0 mg/mg, 30.0 mg, 0.0125 mg
Oral, Tablet, film coated, Tablet, film coated - Oral, , Tablet, Tablet - Oral, Capsule - Oral, Capsule, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, coated, Tablet, coated - Oral
Warnings
Methyldopa And Hydrochlorothiazide has two contraindications. It should not be ingested while encountering any of the conditions given in the following table.Methyldopa And Hydrochlorothiazide ContraindicationsCondition
Risk Level
Notes
Pulse Frequency
Do Not Combine
Anuria
Do Not Combine
Common Methyldopa And Hydrochlorothiazide Drug Interactions
Drug Name
Risk Level
Description
Amifostine
Major
Hydrochlorothiazide may increase the hypotensive activities of Amifostine.
Cyclopentamine
Major
The risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Cyclopentamine.
Dofetilide
Major
The risk or severity of QTc prolongation can be increased when Hydrochlorothiazide is combined with Dofetilide.
Fenofibrate
Major
The therapeutic efficacy of Fenofibrate can be decreased when used in combination with Hydrochlorothiazide.
Hydroxyzine
Major
The risk or severity of QTc prolongation can be increased when Hydrochlorothiazide is combined with Hydroxyzine.
Methyldopa And Hydrochlorothiazide Toxicity & Overdose RiskThe lowest toxic dose of hydrochlorothiazide for mice and rats is more than 10g/kg. Symptoms of overdose include low levels of potassium, chloride, and sodium in the blood. Treatment for hydrochlorothiazide overdose includes rehydration with fluids and electrolytes, medications to raise blood pressure, and oxygen therapy to help with any breathing difficulties.
Methyldopa And Hydrochlorothiazide Novel Uses: Which Conditions Have a Clinical Trial Featuring Methyldopa And Hydrochlorothiazide?
Currently, 158 active trials are researching the potential of Methyldopa and Hydrochlorothiazide to mitigate Cirrhosis, Edema and Congestive Heart Failure.Condition
Clinical Trials
Trial Phases
Antihypertensive Treatment
0 Actively Recruiting
Stroke
11 Actively Recruiting
Not Applicable, Phase 1, Phase 2, Phase 3
Renal tubular acidosis
0 Actively Recruiting
blood pressure inadequately controlled with monotherapy
0 Actively Recruiting
Ascites
10 Actively Recruiting
Phase 3, Not Applicable, Phase 1, Phase 2
Diabetes Insipidus
1 Actively Recruiting
Phase 1
hypokalemia with solo treatment
0 Actively Recruiting
inadequate control of blood pressure with monotherapy
0 Actively Recruiting
Hypertensive disease
19 Actively Recruiting
Not Applicable, Phase 1, Phase 2, Phase 3
calcium channel blockers
0 Actively Recruiting
Antepartum magnesium sulfate prophylaxis
18 Actively Recruiting
Phase 1, Not Applicable, Phase 3, Early Phase 1, Phase 2, Phase 4
Swollen feet or ankles
40 Actively Recruiting
Phase 1, Phase 2, Not Applicable, Early Phase 1, Phase 3, Phase 4
Nephrolithiasis
0 Actively Recruiting
Congestive Heart Failure
23 Actively Recruiting
Phase 2, Phase 3, Not Applicable, Phase 1
Cirrhosis
50 Actively Recruiting
Phase 1, Phase 2, Not Applicable, Phase 4, Phase 3, Early Phase 1
inadequate response to other therapeutic measures
0 Actively Recruiting
Diuretics
0 Actively Recruiting
Bedrest
0 Actively Recruiting
Therapeutic procedure
0 Actively Recruiting
Sodium retention
0 Actively Recruiting
Methyldopa And Hydrochlorothiazide Reviews: What are patients saying about Methyldopa And Hydrochlorothiazide?
4Patient Review
3/20/2008 When I first started taking this medication, it made me very drowsy. Please be cautious and avoid driving long distances until you know how it will affect you.
Patient Q&A Section about methyldopa and hydrochlorothiazide
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.What is contraindicated with methyldopa?
"Methyldopa should not be used in patients who have active hepatic disease, such as acute hepatitis or active cirrhosis. It should also not be used in patients who have previously had liver disorders associated with methyldopa therapy, or who are hypersensitive to any of the product's components."
Answered by AI
Can I take methyldopa with hydrochlorothiazide?
"This combination treatment is used to lower high blood pressure by relaxing blood vessels and removing excess water and salt from the body."
Answered by AI
Does methyldopa cause frequent urination?
"You may feel unusually tired when you start taking this medicine, and you may also urinate more often."
Answered by AI
What drugs interact with methyldopa?
"Do not take methyldopa if you are using drugs called monoamine oxidase inhibitors (MAOIs). These include isocarboxazid, phenelzine, linezolid and tranylcypromine."
Answered by AI